Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097 · cited 3×
“The median survival of BCLC C patients treated with sorafenib is about 10 months in Western countries and even lower in eastern countries [17,25].”
BackgroundInfluentialEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089 · cited 1×
“These findings may radically change the prognostic evaluation and management of HCC patients, suggesting that BCLC stage does not influence the prognostic impact of different therapeutical approaches [18], and that liver resection should be preferred when technically feasible and clinically appropriate [11].”
BackgroundLlovet, J. M., Ducreux, M. P., Lencioni, R. A., Bisceglie, A. M. D., Dufour, J., Greten, T. F., Raymond, É., Roskams, T., Mazzaferro, V., Bruix, J., et al. (2012) · Cited by 1,488
Livraghi, T., Meloni, F., Di Stasi, M., Rolle, E., Solbiati, L., Tinelli, C., & Rossi, S. (2008) · Hepatology · doi:10.1002/hep.21933 · Cited by 1,103
Burroughs, A., Dufour, J.-F., Galle, P., Mazzaferro, V., Piscaglia, F., Raoul, J., Sangro, B., & Bolondi, L. (2013) · Seminars in Liver Disease · doi:10.1055/s-0032-1329906 · Cited by 641 · cited 3×
“The main limit of BCLC is the great prognostic heterogeneity within each stage [2].”
BackgroundMethodSelf-citationPrognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort†
Marrero, J. A., Fontana, R. J., Barrat, A., Askari, F., Conjeevaram, H. S., Su, G. L., & Lok, A. S. (2005) · Hepatology · doi:10.1002/hep.20636 · Cited by 637
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationLlovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Wang, Y.-Y., Zhong, J.-H., Su, Z.-Y., Huang, J.-F., Lu, S.-D., Xiang, B.-D., Ma, L., Qi, L.-N., Ou, B.-N., & Li, L.-Q. (2016) · British Journal of Surgery · doi:10.1002/bjs.10095 · Cited by 318
Treatment Strategies for Hepatocellular Carcinoma—A Multidisciplinary Approach
Lurje, I., Czigany, Z., Bednarsch, J., Roderburg, C., Isfort, P., Neumann, U. P., & Lurje, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061465 · Cited by 229
“The authors concluded that in BCLC B and C patients, resection may also offer survival benefits over locoregional therapies, and should therefore be preferred whenever technically feasible [28].”
BackgroundHyun, M. H., Lee, Y., Kim, J. H., Lee, C. U., Jung, Y. K., Seo, Y. S., Yim, H. J., Yeon, J. E., & Byun, K. S. (2018) · Hepatology · doi:10.1002/hep.29883 · Cited by 219
“TA C E: 8 5 (9 3 ) 5 4 6 1 0 9 0 /1 < 4 0 0 (2 0 % )”
BackgroundInfluentialVitale, A., Trevisani, F., Farinati, F., & Cillo, U. (2020) · Hepatology · doi:10.1002/hep.31187 · Cited by 183
Self-citationPersonalized treatment of patients with very early hepatocellular carcinoma
Vitale, A., Peck-Radosavljevic, M., Giannini, E. G., Vibert, E., Sieghart, W., Van Poucke, S., & Pawlik, T. M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.012 · Cited by 168
Self-citation
Metadata
- Authors
- Vitale, A., Burra, P., Frigo, A. C., Trevisani, F., Farinati, F., Spolverato, G., Volk, M., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Cabibbo, G., Felder, M., Gasbarrini, A., Sacco, R., Foschi, F. G., Missale, G., Morisco, F., Svegliati Baroni, G., Virdone, R., & Cillo, U.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 62
- Issue
- 3
- Pages
- 617-624
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1995319315
- Cited by
- 211
- References
- 28
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.